Home2018-07-27T04:33:28+00:00

Novel cancer therapies targeting key cancer pathways

READ MORE
Prescient Therapeutics PTX

We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.

prescient therapeutics

OUR COMPANY

Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Digital Brochure

Two Page Fact Sheet

prescient therapeutics

OUR SCIENCE

Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.

prescient therapeutics

LATEST NEWS

26/08/2019Appendix 4E and 2019 Annual ReportPDF
26/08/2019Corporate Governance Statement and Appendix 4GPDF
24/07/2018June 2019 Appendix 4C - QuarterlyPDF
11/07/2019PTX Initiates Phase 1b Clinical Trial for PTX-100
30/05/2019Change to Exercise Price of OptionsPDF
21/05/2019Investor Presentation - May 2019PDF
21/05/2019Prescient to present at Sydney ConferencePDF